Cost effective clinical trials are being provided in various countries in Asia and Eastern Europe, the main reason for this is to increase the growth and revenue for this specialist industry, This has had an impact on many Pharmaceutical and Bio-tech companies who are now outsourcing the clinical trial research to these countries. The attraction of these emerging markets is acknowledged by many in the industry; where an expanding middle class allows for more healthcare spending and where there are a number of willing and treatment-naïve volunteers available to recruit.
The conduct of Clinical Trials has become cost effective in these countries.
Due to the vast increase in research, sales and production in these regions, CRO’s (clinical research organisations), biotech and pharmaceutical companies are now being challenged with ethical business problems. Due to a lack in logistical and institutional capacity, many of these countries are faced with situations which lead to government representatives and business leaders accepting bribes or becoming involved in other corrupt acts with the aim of securing approval to conduct a certain clinical trial, or acquiring the materials to conduct these studies.
The Corruptions Perceptions Index, examined by Transparency International (a not-for-profit organisation based in Berlin), affords a basis for which the threat of corruption can be approximated.The index is intended to rate countries based on the opinions of state analysts and business executives.China was ranked seventy-second, Brazil at eightieth and India ranked eighty-fifth out of a total of 180 countries, where the country ranked the lowest would be considered to be the least corrupt.
Pharmaceutical and Biotechnology organisations need to consider this before looking to outsource their studies in other countries. They need to be fully aware of the ethical violations that there CRO partners may encounter. If these organisations are ignorant towards this, the clinical trial may in turn be jeopardised or the trial outcome report could be made invalid if the CRO carrying out the study have breeched any ethics violations that may be in place. This could be detrimental for the organisation’s reputation, and could hinder any business in that country for the future.
Nicky Hargreaves has over 24 years in R&D, manufacturing, quality and regulatory affairs.”Trusted UK based Clinical Research organisations or pharmacology companies who provide professional clinical trials (providing the statistical analysis, Clinical Data Management and the clinical research) that assists with the development of new drug entities are known to be the top resource.” Says Nicky; who is a microbiologist by training and has managed projects in numerous divisions, including pharmaceutical, medicinal, OTC, oral healthcare and animal healthcare.
* Before taking any medical advise you should consult your doctor. *
Related posts:
- Multiple Sclerosis: What is it and who’s at risk? The word Multiple Sclerosis comes from the Latin words multus...
- Prostate Cancer recently, the number of men who have cancer of the...
- A Promising Career is on the Horizon as a Clinical Esthetician Are you on the cusp of adulthood without a plan,...
- Advice on Utilizing a Foreign Exchange Firm. Newcomers Guide to Foreign Exchange The foreign exchange business has frequently featured in the papers...
- Free Colon Cleanse Trials – Why Didn’t I Take The Plunge Sooner? Thoughtlessly, I put my assurance in the establishment for decades...
